Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs

  • Authors:
    • Takumi Ochiai
    • Kazuhiko Nishimura
    • Tomoo Watanabe
    • Masayuki Kitajima
    • Akinori Nakatani
    • Takashi Inou
    • Hideki Shibata
    • Tsuyoshi Sato
    • Kenji Kishine
    • Shougo Seo
    • Satoshi Okubo
    • Shunji Futagawa
    • Satomi Mashiko
    • Isao Nagaoka
  • View Affiliations

  • Published online on: May 30, 2013     https://doi.org/10.3892/mco.2013.136
  • Pages: 805-810
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Serum iron levels have been reported to increase following the administration of various anticancer drugs. an increase in serum iron levels during therapy with leucovorin and fluorouracil plus oxaliplatin (FOLFOX) or leucovorin and fluorouracil plus irinotecan (FOLFIRI) was also observed. The aim of this study was to investigate the correlation between serum iron levels and prognosis in advanced colorectal cancer (CRC) patients treated with FOLFOX/FOLFIRI ± molecularly‑targeted drugs. Serum iron levels were measured prior to and at 48 h after treatment with FOLFOX/FOLFIRI ± molecularly‑targeted drugs in 72 advanced CRC patients, all of whom succumbed to the disease between December, 2005 and February, 2012. No patients received radiotherapy. Taking the median rate of increase in serum iron levels as the cut‑off value in each therapy, the patients were divided into cohort I (increase rate greater than the cut‑off value in at least one therapy) or cohort II (increase rate less than the cut‑off value in all therapies). The χ2 test and the t‑test were used to compare patient characteristics between the two cohorts. Prognosis was evaluated between the two cohorts using the Kaplan‑Meier method, the log‑rank test and the Cox proportional hazards regression analysis. No significant bias in patient characteristics (including the frequency of chemotherapy or number of patients treated with molecularly‑targeted drugs) was observed between the two cohorts. Serum iron levels were transiently elevated following treatment (P<0.001), returning to baseline within 2 weeks. Median survival time (MST) in cohort I (n=44) and cohort II (n=28) was 430 and 377 days, respectively. The MST was significantly higher in cohort I (P=0.0382). The multivariate analysis identified a small increase in serum iron levels as an independent risk factor for overall survival (OS). These results suggest that serum iron levels may be used as a new predictive factor in FOLFOX/FOLFIRI ± molecularly‑targeted drug therapy. Serum iron levels may therefore prove to be a useful and convenient biomarker for OS in CRC patients.
View Figures
View References

Related Articles

Journal Cover

September 2013
Volume 1 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Nakatani, A., Inou, T. ... Nagaoka, I. (2013). Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs. Molecular and Clinical Oncology, 1, 805-810. https://doi.org/10.3892/mco.2013.136
MLA
Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Nakatani, A., Inou, T., Shibata, H., Sato, T., Kishine, K., Seo, S., Okubo, S., Futagawa, S., Mashiko, S., Nagaoka, I."Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs". Molecular and Clinical Oncology 1.5 (2013): 805-810.
Chicago
Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Nakatani, A., Inou, T., Shibata, H., Sato, T., Kishine, K., Seo, S., Okubo, S., Futagawa, S., Mashiko, S., Nagaoka, I."Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs". Molecular and Clinical Oncology 1, no. 5 (2013): 805-810. https://doi.org/10.3892/mco.2013.136